Metabolic cardioprotection by pyruvate: Recent progress

Experimental Biology and Medicine

Volumn 230, Issue 7, 2005, Pages 435-443

  Mallet, Robert T ^a   Sun, Jie ^a   Knott, E Marty ^a   Sharma, Arti B ^a   Olivencia Yurvati, Albert H ^b  

^a UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER   (United States)

^b University of North Texas Health Science Center   (United States)

Author keywords

Antioxidant; Bypass surgery; Cardiac stunning; Cardiopulmonary resuscitation; Ethyl pyruvate; Infarction; Myocardial ischemia; Phosphorylation potential; Reactive oxygen species

Indexed keywords

ANTIOXIDANT; PYRUVIC ACID; REACTIVE OXYGEN METABOLITE;

ANIMAL EXPERIMENT; ANIMAL MODEL; BYPASS SURGERY; CALCIUM TRANSPORT; CONTROLLED STUDY; HEART FAILURE; HEART MUSCLE CONTRACTILITY; HEART MUSCLE ISCHEMIA; HEART MUSCLE METABOLISM; HEART PERFORMANCE; HEART PROTECTION; NONHUMAN; OXIDATIVE STRESS; PHOSPHORYLATION; REPERFUSION INJURY; RESUSCITATION; SHORT SURVEY; STUNNED HEART MUSCLE; SWINE;

EID: 21544445251     PISSN: 15353702     EISSN: None     Source Type: Journal    
DOI: 10.1177/153537020523000701     Document Type: Short Survey

References (90)

1. Mallet RT. Pyruvate: metabolic protector of cardiac performance. Proc Soc Exp Biol Med 223:136-148, 2000.
2. Panchal AR, Comte B, Huang H, Kerwin T, Darvish A, Des Rosiers C, Brunengraber H, Stanley WC. Partitioning of pyruvate between oxidation and anaplerosis in swine hearts. Am J Physiol Heart Circ Physiol 279:H2390-H2398, 2000.
3. Panchal AR, Comte B, Huang H, Dudar B, Roth B, Chandler M, Des Rosiers C, Brunengraber H, Stanley WC. Acute hibernation decreases myocardial pyruvate carboxylation and citrate release. Am J Physiol Heart Circ Physiol 281:H1613-H1620, 2001.
4. Lloyd S, Brocks C, Chatham JC. Differential modulation of glucose, lactate, and pyruvate oxidation by insulin and dichloroacetate in the rat heart. Am J Physiol Heart Circ Physiol 285:H163-H172, 2003.
5. 13C-labeled substrates: focusing on the origin and fate of pyruvate and citrate carbons. Am J Physiol Heart Circ Physiol 286:H1461-H1470, 2004.
6. Lloyd SG, Wang P, Zeng H, Chatham JC. Impact of low-flow ischemia on substrate oxidation and glycolysis in the isolated perfused rat heart. Am J Physiol Heart Circ Physiol 287:H351-H362, 2004.
7. Sharma AB, Knott EM, Bi J, Martinez RR, Sun J, Mallet RT. Pyruvate improves cardiac electromechanical and metabolic recovery from cardiopulmonary arrest and resuscitation. Resuscitation (in press), 2005.
8. Mongan PD, Fontana JL, Chen R, Bünger R. Intravenous pyruvate prolongs survival during hemorrhagic shock in swine. Am J Physiol Heart Circ Physiol 277:H2253-H2263, 1999.
9. Mongan PD, Cappachione J, Fontana JL, West S, Bünger R. Pyruvate improves cerebral metabolism during hemorrhagic shock. Am J Physiol Heart Circ Physiol 281:H854-H864, 2001.
10. Owen OE, Mozzoli MA, Boden G, Patel MS, Reichard GA Jr, Trapp V, Shuman CR, Felig P. Substrate, hormone, and temperature responses in males and females to a common breakfast. Metabolism 29:511-523, 1980.
11. Meierhenrich R, Jedicke H, Voigt A, Lange H. The effect of erythropoietin on lactate, pyruvate, and excess lactate under physical exercise in dialysis patients. Clin Nephrol 45:90-96, 1996.
12. Zweier JL, Jacobus WE. Substrate-induced alterations of high energy phosphate metabolism and contractile function in the perfused heart. J Biol Chem 262:8015-8021, 1987.
13. 2+ uptake. Biochim Biophys Acta 1224:22-32, 1994.
14. Mallet RT, Sun J. Mitochondrial metabolism of pyruvate is required for its enhancement of cardiac function and energetics. Cardiovasc Res 42:149-161, 1999.
15. Bünger R, Mallet RT, Hartman DA. Pyruvate-enhanced phosphorylation potential and inotropism in normoxic and postischemic isolated working heart: near-complete prevention of reperfusion contractile failure. Eur J Biochem 180:221-233, 1989.
16. Ochiai K, Zhang J, Gong G, Zhang Y, Liu J, Ye Y, Wu X, Liu H, Murakami Y, Bache RJ, Ugurbil K, From AHL. Effects of augmented delivery of pyruvate on myocardial high-energy phosphate metabolism at high workstate. Am J Physiol Heart Circ Physiol 286:H2237-H2242, 2004.
17. Kammermeier H. High energy phosphate of the myocardium: concentration versus free energy change. Basic Res Cardiol 82:31-36, 1987.
18. 19F nuclear magnetic resonance study. Circ Res 83:898-907, 1998.
19. Fabiato A. Calcium-induced release of calcium from the cardiac sarcoplasmic reticulum. Am J Physiol Cell Physiol 245:C1-C14, 1983.
20. Martin BJ, Valdivia HH, Bünger R, Lasley RD, Mentzer RM Jr. Pyruvate augments calcium transients and cell shortening in rat ventricular myocytes. Am J Physiol Heart Circ Physiol 274:H8-H17, 1998.
21. 2+ regulation in cardiac myocytes from normal and diabetic rats. Clin Exp Pharmacol Physiol 26:889-897, 1999.
22. 2+ release in rats via mitochondria-dependent and -independent mechanisms. J Physiol 550:765-783, 2003.
23. Hüser J, Wang YG, Sheehan KA, Cifuentes F, Lipsius SL, Blatter LA. Functional coupling between glycolysis and excitation-contraction coupling underlies alternans in cat heart cells. J Physiol 524:795-806, 2000.
24. 2+ waves in cat atrial myocytes. J Physiol 545:65-79, 2002.
25. 2+ in rabbit cardiac muscle preparations. Am J Physiol Heart Circ Physiol 279:H702-H708, 2000.
26. Halestrap AP, Price NT. The proton-linked monocarboxylate transporter (MCT) family: structure, function and regulation. Biochem J 343:281-299, 1999.
27. 2+-content in blunted inotropic responsiveness of failing human myocardium. J Mol Cell Cardiol 34:455-467, 2002.
28. Kentish JC. The effects of inorganic phosphate and creatine phosphate on force production in skinned muscles from rat ventricle. J Physiol 370:585-604, 1986.
29. Kawai M, Güth K, Winnikes K, Haist C, Rüegg JC. The effect of inorganic phosphate on the ATP hydrolysis rate and the tension transients in chemically skinned rabbit psoas fibers. Pflügers Arch 408:1-9, 1987.
30. 2+-sensitizing property of xanthine oxidase inhibitors. Circ Res 83:423-430, 1998.
31. 2+ cycling in isolated failing human myocardium. Circulation 105:194-199, 2002.
32. 2+ sensitivity of skinned cardiac muscle with troponin C exchange. Implications for myocardial ischemia. FEBS Lett 245:279-282, 1989.
33. 2+ activation. Biochemistry 33:8464-8471, 1994.
34. 2+-sensitizer Org-30029 reverses acidosis- and BDM-induced contractile depression in canine myocardium. Am J Physiol Heart Circ Physiol 271:H1829-H1839, 1996.
35. Bolli R, Marbán E. Molecular and cellular mechanisms of myocardial stunning. Physiol Rev 79:609-634, 1999.
36. Ambrosio G, Tritto I. Reperfusion injury: experimental evidence and clinical implications. Am Heart J 138:869-575, 1999.
37. Gross GJ, Kersten JR, Warltier DC. Mechanisms of postischemic contractile dysfunction. Ann Thorac Surg 68:1898-1904, 1999.
38. Lefer DJ, Granger DN. Oxidative stress and cardiac disease. Am J Med 109:315-323, 2000.
39. Kaminski KA, Bonda TA, Korecki J, Musial WJ. Oxidative stress and neutrophil activation - the two keystones of ischemia/reperfusion injury. Int J Cardiol 86:41-59, 2002.
40. Chatham JC, Gilbert HF, Radda GK. The metabolic consequences of hydroperoxide perfusion on the isolated rat heart. Eur J Biochem 184:657-662.
41. Janero DR, Hreniuk D, Sharif HM. Hydroperoxide-induced Oxidative stress impairs heart muscle cell carbohydrate metabolism. Am J Physiol Cell Physiol 266:C179-C188, 1994.
42. Slater AFG, Nobel SI, Orrenius S. The role of intracellular oxidants in apoptosis. Biochim Biophys Acta 1271:59-62, 1995.
43. Vaage J, Antonelli M, Bufi M, Irtun O, DeBlasi RA, Corbucci GG, Gasparetto A, Semb AG. Exogenous reactive oxygen species deplete the isolated rat heart of antioxidants. Free Radie Biol Med 22:85-92, 1997.
44. Tretter L, Adam-Vizi V. Inhibition of Krebs cycle enzymes by hydrogen peroxide: a key role of α-ketoglutarate dehydrogenase in limiting NADH production under oxidative stress. J Neurosci 20:8972-8979, 2000.
45. Eaton P, Hearse DJ, Shattock MJ. Lipid hydroperoxide modification of proteins during myocardial ischemia. Cardiovasc Res 51:294-303.
46. Mallet RT, Sun J. Antioxidant properties of myocardial fuels. Mol Cell Biochem 253:103-111, 2003.
47. Constantopoulos G, Barranger JA. Nonenzymatic decarboxylation of pyruvate. Anal Biochem 139:353-358, 1984.
48. DeBoer LWV, Bekx PA, Han L, Steinke L. Pyruvate enhances recovery of rat hearts after ischemia and reperfusion by preventing free radical generation. Am J Physiol Heart Circ Physiol 265:H1571-H1576, 1993.
49. Crestanello JA, Kamelgard J, Whitman GJR. The cumulative nature of pyruvate's dual mechanism for myocardial protection. J Surg Res 59:198-204, 1995.
50. Leon H, Atkinson LL, Sawicka J, Strynadka K, Lopaschuk GD, Schulz R. Pyruvate prevents cardiac dysfunction and AMP-activated protein kinase activation by hydrogen peroxide in isolated rat hearts. Can J Physiol Pharmacol 82:409-416, 2004.
51. Vásquez-Vivar J, Denicola A, Radi R, Augusto O. Peroxynitrite-mediated decarboxylation of pyruvate to both carbon dioxide and carbon dioxide radical anion. Chem Res Toxicol 10:786-794, 1997.
52. 13C mass isotopomer study of anaplerotic pyruvate carboxylation in perfused rat hearts. J Biol Chem 272:26125-26131, 1997.
53. Schafer FQ, Buettner GR. Redox environment of the cell as viewed through the redox state of the glutathione disulfide/glutathione couple. Free Radic Biol Med 30:1191-1212, 2001.
54. Tejero-Taldo MI, Caffrey JL, Sun J, Mallet RT. Antioxidant properties of pyruvate mediate its potentiation of β-adrenergic inotropism in stunned myocardium. J Mol Cell Cardiol 31:1863-1872, 1999.
55. Mallet RT, Squires JE, Bhatia S, Sun J. Pyruvate restores contractile function and antioxidant defenses of hydrogen peroxide-challenged myocardium. J Mol Cell Cardiol 34:1173-1184, 2002.
56. Bassenge E, Sommer O, Schwemmer M, Bünger R. Antioxidant pyruvate inhibits cardiac formation of reactive oxygen species through changes in redox state. Am J Physiol Heart Circ Physiol 279:H2431-H2438, 2000.
57. 2 modulate superoxide anion production in bovine cardiac myocytes: potential role of NADH oxidase. Circulation 96:614-620, 1997.
58. Zhou Z, Lasley RD, Hegge O, Bünger R, Mentzer RM. Myocardial stunning: a therapeutic conundrum. J Thorac Cardiovasc Surg 110:1391-1401, 1995.
59. Tejero-Taldo MI, Sun J, Caffrey JL, Mallet RT. Pyruvate potentiates β-adrenergic inotropism of stunned guinea-pig myocardium. J Mol Cell Cardiol 30:2327-2339, 1998.
60. Squires JE, Sun J, Caffrey JL, Yoshishige D, Mallet RT. Acetoacetate augments β-adrenergic inotropism of stunned myocardium by an antioxidant mechanism. Am J Physiol Heart Circ Physiol 284:H1340-H1347, 2003.
61. Hermann H-P, Zeitz O, Lehnart SE, Keweloh B, Datz N, Hasenfuss G, Janssen PML. Potentiation of beta-adrenergic inotropic response by pyruvate in failing human myocardium. Cardiovasc Res 53:116-123, 2002.
62. Hermann H-P, Pieske B, Schwarzmüller E, Keul J, Just H, Hasenfuss G. Haemodynamic effects of intracoronary pyruvate in patients with congestive heart failure: an open study. Lancet 353:1321-1323, 1999.
63. Hermann H-P, Arp J, Pieske B, Kögler H, Baron S, Janssen PML, Hasenfuss G. Improved systolic and diastolic myocardial function with intracoronary pyruvate in patients with congestive heart failure. Eur J Heart Fail 6:213-218, 2004.
64. Regitz V, Azumi T, Stephan H, Naujocks S, Schaper W. Biochemical mechanism of infarct size reduction by pyruvate. Cardiovasc Res 15:652-658, 1981.
65. Gutterman DD, Chilian WM, Eastham CL, Inou T, White CW, Marcus ML. Failure of pyruvate to salvage myocardium after prolonged ischemia. Am J Physiol Heart Circ Physiol 250:H114-H120, 1986.
66. Kristo G, Yoshimura Y, Niu J, Keith BJ, Mentzer RM Jr, Lasley RD. The intermediary metabolite pyruvate attenuates stunning and reduces infarct size in in vivo porcine myocardium. Am J Physiol Heart Circ Physiol 286:H517-H524, 2004.
67. Stanley WC, Kivilo KM, Panchal AR, Hallowell PH, Bomont C, Kasumov T, Brunengraber H. Post-ischemic treatment with dipyruvyl-acetyl-glycerol decreases myocardial infarct size in the pig. Cardiovasc Drugs Ther 17:209-216, 2003.
68. Thel MC, O'Connor CM. Cardiopulmonary resuscitation: historical perspective to recent investigations. Am Heart J 137:39-48, 1999.
69. Eisenberg MS, Mengen TJ. Cardiac resuscitation. New Engl J Med 344:1304-1313, 2001.
70. Cerchiari EL, Safar P, Klein E, Cantadore R, Pinsky M. Cardiovascular function and neurologic outcome after cardiac arrest in dogs: the cardiovascular post-resuscitation syndrome. Resuscitation 25:9-33, 1993.
71. Kern KB. Postresuscitation myocardial dysfunction. Cardiol Clin 20:89-101, 2002.
72. Safar P, Xiao F, Radovsky A, Tanigawa K, Ebmeyer U, Bircher N, Alexander H, Stezoski SW. Improved cerebral resuscitation from cardiac arrest in dogs with mild hypothermia plus blood flow promotion. Stroke 27:105-113, 2002.
73. Kern KB, Hilwig RW, Rhee KH, Berg RA. Myocardial dysfunction after resuscitation from cardiac arrest: an example of global myocardial stunning. J Am Coll Cardiol 28:232-240, 1996.
74. Olivencia-Yurvati AH, Blair SL, Baig M, Mallet RT. Pyruvate-enhanced cardioprotection during surgery with cardiopulmonary bypass. J Cardiothorac Vase Anesth 17:715-720, 2003.
75. Mangano DT. Biventricular function after myocardial revascularization in humans: deterioration and recovery patterns during the first 24 hours. Anesthesiology 62:571-577, 1985.
76. Breisblatt WM, Stein KL, Wolfe CJ, Follansbee WP, Capozzi J, Armitage JM, Hardesty RL. Acute myocardial dysfunction and recovery: a common occurrence after coronary bypass surgery. J Am Coll Cardiol 15:1261-1269, 1990.
77. Royster RL. Myocardial dysfunction following cardiopulmonary bypass: recovery patterns, predictors of inotropic need, theoretical concepts of inotropic administration. J Cardiothorac Vase Anesth 7:19-25, 1993.
78. Savaris N, Polanczyk C, Clausell N. Cytokines and troponin-I in cardiac dysfunction after coronary artery grafting with cardiopulmonary bypass. Arq Bras Cardiol 77:114-119, 2001.
79. Sakamoto H, Corcoran TB, Laffey JG, Shorten GD. Isoprostanes-markers of ischaemia reperfusion injury. Eur J Anaesthesiol 19:550-559, 2002.
80. Mehlhom U, Krahwinkel A, Geissler HJ, LaRosee K, Fischer UM, Klass O, Suedkamp M, Hekmat K, Tossios P, Bloch W. Nitrotyrosine and 8-isoprostane formation indicate free radical-mediated injury in hearts of patients subjected to cardioplegia. J Thorac Cardiovasc Surg 125:178-183, 2003.
81. Knott EM, Ryou M-G, Sun J, Heymann A, Martinez RR, Sharma AB, Mallet RT, O-Yurvati AH. Pyruvate cardioplegia suppresses oxidative stress and preserves phosphorylation potential of arrested myocardium (abstract). FASEB J 19:A 690, 2005.
82. Montgomery CM, Fairhurst AS, Webb JL. Metabolic studies on heart mitochondria. III. The action of parapyruvate on α-ketoglutaric oxidase. J Biol Chem 221:369-376, 1956.
83. 14, purity and stability. Anal Biochem 8:171-178, 1964.
84. Margolis SA, Coxon B. Identification and quantitation of the impurities in sodium pyruvate. Anal Biochem 58:2504-2510, 1986.
85. Montgomery CM, Webb JL. Metabolic studies on heart mitochondria. III. The inhibitory action of parapyruvate on the tricarboxylic acid cycle. J Biol Chem 221:359-368, 1956.
86. Varma SD, Devamanoharan PS, Ali AH. Prevention of intracellular oxidative stress to lens by pyruvate and its ester. Free Radic Res 28:131-135, 1998.
87. Sims CA, Wattanasirichaigoon S, Menconi MJ, Ajami AM, Fink MP. Ringer's ethyl pyruvate solution ameliorates ischemia/reperfusion-induced intestinal mucosal injury in rats. Crit Care Med 29:1513-1518, 2001.
88. Uchiyama T, Delude RL, Fink MP. Dose-dependent effects of ethyl pyruvate in mice subjected to mesenteric ischemia and reperfusion. Intensive Care Med 29:2050-2058, 2003.
89. Woo YJ, Taylor MD, Cohen JE, Jayasankar V, Bish LT, Burdick J, Pirolli TJ, Berry MF, Hsu V, Grand T. Ethyl pyruvate preserves cardiac function and attenuates oxidative injury after prolonged myocardial ischemia. J Thorac Cardiovasc Surg 127:1262-1269, 2004.
90. Pütter J, Becker R. Peroxidases. In: Bergmeyer HU, Ed. Methods of Enzymatic Analysis (3rd ed.). New York: Academic Press, Vol 3: pp 286-293, 1983.